Humana Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -40

A Look At Humana (HUM) Valuation After Earnings Miss And Lower Full Year Guidance

AI-generated analysis

πŸ“‰ Humana missed its quarterly earnings expectations and lowered its full-year guidance following the recent financial release.

πŸ“ˆ Despite the mixed fundamental news, Humana's stock price jumped 33.81% over the last month, though longer-term returns remain weak at 5.83% over one year.

βš–οΈ The company's current share price of $237.96 is trading above its calculated narrative fair value of $212.87, suggesting it may be 11.8% overvalued.

🧾 Management confirmed that the previously announced share repurchase program has been fully completed.

⚠️ Regulatory compliance within the expanding Medicare Advantage segment is cited as a central factor influencing Humana's valuation and margins.

πŸ’° While the stock trades near analyst targets, its P/E ratio of 25.3x is below its estimated fair ratio of 39.4x but higher than the broader US healthcare industry average.

πŸ” Simply Wall St analysis flags that recent weakness could either represent a buying opportunity or reflect market pricing of future growth risks.

βš™οΈ Investors are encouraged to evaluate whether current regulatory pressures will ease if Humana's compliance investments successfully reduce audit and documentation risks.

πŸ“Š The discrepancy between the overvaluation signal and lower P/E multiples suggests the market is currently pricing in specific business risks for the insurer.

πŸ› οΈ Analysts note that treating compliance as an operational framework rather than a checklist could be key to long-term profitability in Medicare Advantage.

πŸš€ Simply Wall St offers various screeners to help investors find other undervalued, dividend-focused, or solid balance sheet healthcare opportunities alongside Humana.

⚑ The article concludes with standard disclaimers stating that the analysis is not financial advice and does not constitute a recommendation to buy or sell stock.

Bullish Signals
  • Humana's stock has experienced a sharp 33.81% return over the past month, indicating recent positive momentum despite lower earnings guidance.
  • The company recently completed its previously announced share repurchase program, which supports shareholder value and capital allocation discipline.
  • Although trading at $237.96, Humana carries an intrinsic value estimate of $212.87, creating a narrative valuation gap that could offer a margin of safety if sentiment improves.
  • The current P/E ratio of 25.3x is notably below the estimated fair ratio of 39.4x and under the peer average of 32.4x, suggesting potential upside as expectations reset.
  • Future profitability could improve significantly if regulatory intensity eases or if the company's compliance investments successfully reduce audit and documentation risks.
Risk Factors
  • Humana's first quarter earnings miss and lower full year guidance have coincided with a 11.8% overvaluation status according to its intrinsic value estimate of $212.87 versus the last close of $237.96.
  • The company's long-term performance remains weak, with a 1-year total shareholder return of only 5.83% and a 3-year total shareholder return of 53.98%, indicating a difficult multi-year stretch for holders.
  • Humana faces regulatory headwinds where compliance is becoming a critical operational framework required to thrive as Medicare Advantage continues to expand.
  • The current P/E ratio of 25.3x is below the estimated fair ratio of 39.4x and under the 32.4x peer average, suggesting investors are pricing in significant business-specific risks.
  • Valuation concerns are compounded by the question of whether the gap between fair value and current price represents a margin of safety or a valuation trap.
Full Analysis
Humana (HUM) recently reported first quarter earnings that missed analyst expectations, leading the company to lower its full year guidance. Despite these negative financial updates, the stock has experienced a sharp 33.81% gain in the past month, though its one-year and three-year total shareholder returns remain weak at 5.83% and 53.98%, respectively. The article highlights that Humana has successfully completed a previously announced share repurchase program, signaling capital return to shareholders despite current operational pressures. Valuation analysis presented in the content suggests a discrepancy between market price and intrinsic value, noting a trading price of $237.96 compared to an estimated fair value of $212.87, which characterizes the stock as 11.8% overvalued based on a discounted cash flow narrative. However, this perceived overvaluation is contrasted with Humana's current Price-to-Earnings ratio of 25.3x, which is actually below its estimated fair ratio of 39.4x and under the peer group average of 32.4x, though slightly above the broader US healthcare industry level. The core drivers of Humana's valuation story are centered on regulatory risks associated with the expanding Medicare Advantage program. The analysis emphasizes that future success depends on treating compliance as an embedded operational framework rather than a mere checkbox, specifically regarding billing and clinical review systems to mitigate audit and documentation risks. While the primary fair value estimate flags the stock as expensive due to these concerns, the lower P/E ratio suggests that investors may be pricing in specific business risks while still leaving room for the valuation multiple to expand if regulatory intensity eases or compliance investments reduce long-term risks effectively.